Search / Trial NCT00000737

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of May 26, 2024

Completed

Keywords

Weight Loss Megestrol Cachexia Eating Disorders Tetrahydrocannabinol Appetite

Description

HIV-wasting syndrome, which is characterized by severely debilitating anorexia and weight loss, is of particular concern because it can exacerbate the primary illness and is associated with a poor prognosis. Attempts at maintaining body mass through the use of megestrol acetate and dronabinol, two anti-cachectic drugs, may prolong survival. Fifty-six patients are randomized to one of four treatment arms, as follows: high-dose megestrol acetate alone; dronabinol alone; high-dose megestrol acetate combined with dronabinol; or low-dose megestrol acetate combined with dronabinol. Treatment con...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC). If initiating new antiretroviral therapy, patient must have been on a stable dose for at least 4 weeks prior to study entry.
  • Maintenance or suppressive therapy with any of the following, provided patient has been on a stable dose for at least 1 week prior to study entry:
  • Ganciclovir or foscarnet for CMV retinitis.
  • Fluconazole, amphotericin B, or flucytosine for cryptococcosis.
  • Amphotericin B for disseminated histoplasmosis.
  • Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis.
  • Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex.
  • Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis.
  • Any of the following provided patient is on a stable dose for at least 1 week prior to study entry:
  • Trimethoprim-sulfamethoxazole, aerosolized pentamidine, or dapsone for Pneumocystis carinii prophylaxis.
  • Clotrimazole troches, nystatin suspension, ketoconazole, or fluconazole for oral candidiasis.
  • Oral acyclovir for mucocutaneous herpes simplex.
  • Narcotic analgesics, tranquilizers, sedative-hypnotics, or anticholinergic agents provided patient is on a stable dose for at least 1 week prior to study entry.
  • Patients must have:
  • HIV infection.
  • HIV-wasting syndrome and anorexia.
  • Life expectancy of at least 4 months.
  • Ability to tolerate oral therapy, feed themselves, and have access to as much food as they desire with no dietary restrictions.
  • Prior Medication:
  • Allowed:
  • Prior zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC).
  • Prior maintenance or suppressive therapy for certain opportunistic infections, as follows:
  • Ganciclovir or foscarnet for CMV retinitis.
  • Fluconazole, amphotericin B, or flucytosine for cryptococcosis.
  • Amphotericin B for disseminated histoplasmosis.
  • Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis.
  • Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex.
  • Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Major, acute opportunistic infections.
  • Active neoplasms other than Kaposi's sarcoma or localized skin carcinoma.
  • Diabetes, congestive heart failure, clinical ascites, or uncontrolled hypertension.
  • Persistent grade 3/4 diarrhea.
  • Impaired oral intake, such as occurs with Candida esophagitis or severe mouth ulcers.
  • Clinically significant cardiac arrhythmias.
  • Requirement for anticonvulsants for seizure disorder.
  • Concurrent Medication:
  • Excluded:
  • Marijuana use.
  • Anabolic steroids.
  • Anticonvulsants for seizure disorders.
  • Alcohol or barbiturates.
  • Patients with the following prior conditions are excluded:
  • Diagnosis of a major, acute opportunistic infection within 2 months prior to study entry.
  • Hospitalization within 2 weeks prior to study entry.
  • History of hypersensitivity reactions to megestrol acetate, dronabinol, or sesame oil (a component of the dronabinol capsules).
  • History of thromboembolic events.
  • History of psychiatric disorder other than depression.
  • Prior Medication:
  • Excluded:
  • Prior dronabinol.
  • Megestrol acetate within 2 months prior to study entry.
  • Marijuana within 1 month prior to study entry.
  • Anabolic steroids within 3 months prior to study entry.
  • Current drug or alcohol abuse (patients with a history of occasional marijuana use are eligible provided they have abstained from its use for 1 month prior to study entry and agree to refrain from marijuana use for the study period).

Attachments

readout_NCT00000737_2024-05-26.pdf

4.5 MB

NCT00000737_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

New Orleans, Louisiana, United States

Brooklyn, New York, United States

Portland, Oregon, United States

Wichita, Kansas, United States

Denver, Colorado, United States

Chicago, Illinois, United States

Baltimore, Maryland, United States

St Louis, Missouri, United States

Providence, Rhode Island, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0